कोशिश गोल्ड - मुक्त
“Singapore has been a great launchpad, owing to its structured safety frameworks”
BioSpectrum Asia
|BioSpectrum Asia Sep 2025
The increasing prevalence of occupational injuries and illnesses is one of the primary factors fueling the growth of the occupational health market, valued at $5.45 billion in 2025, across the globe. With the Asia Pacific (APAC) region occupying the third-largest share in this market, after the US and Europe, we see a number of companies deploying technologies to unlock tremendous opportunities within the occupational health sector. Singapore-based startup TacnIQ AI is one such example, taking a proactive approach to address the health risks associated with workplace management, through technology. Their flagship product Backy is an artificial intelligence (AI)-powered wearable designed to prevent musculoskeletal injuries in physically demanding jobs. It delivers posture feedback in real time to workers, helping reduce back strain and injury risks. In an exclusive interview with BioSpectrum Asia, TacnIQ's Co-Founder and Chief Executive Officer, Aashish Mehta, shares how the company is navigating product development, adoption challenges, and regulatory compliance as it expands into global markets. Edited excerpts-
-
 
 What are TacnIQ AI's current and future milestones – in terms of product development, launches, partnerships, and global expansion?
Over the past year, we've moved quickly, from concept to pilot to production. Backy is already live with partners like DHL, where it's helping reduce posture-related strain and injury risk by over 65 per cent. We're also working with hospitals to test applications in clinical and eldercare environments. In parallel, we've partnered with the British Standards Institution (BSI) to contribute to emerging digital safety standards.
Looking ahead, we're focused on scaling and evolving the technology. The next version of Backy will feature smarter AI agents that can not only detect unsafe posture but also automatically generate safety guidance and reduce manual reporting.
Geographically, we're expanding beyond Southeast Asia to Europe and North America, especially in logistics, aged care, and manufacturing. We're also working to integrate Backy with insurers and enterprise EHS (Environmental Health and Safety) software so that it becomes a core part of workplace wellness and safety ecosystems, not just a standalone device.
Are you planning to raise more funds this year or next? Please share details.
यह कहानी BioSpectrum Asia के BioSpectrum Asia Sep 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
BioSpectrum Asia से और कहानियाँ
 
 BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
New Zealand to lead new gene therapy trial for muscular dystrophy
The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Scientists in Australia grow living skin in world-first
Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare
HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund
Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan
Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium
Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Korea makes smart patch that can run tests using sweat instead of blood
A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka
The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.
1 min
BioSpectrum Asia Oct 2025
 
 BioSpectrum Asia
Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines
China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.
1 min
BioSpectrum Asia Oct 2025
Listen
Translate
Change font size

